Delving into the Latest Updates on Radium Ra-223 Dichloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Therapeutic radiopharmaceuticals

Synonyms

Alpharadin, Radium chloride Ra-223, Radium Ra 223 dichloride

+ [20]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors), Ionising radiation emitters

Therapeutic Areas

NeoplasmsUrogenital DiseasesSkin and Musculoskeletal Diseases

Active Indication

Prostatic CancerBone metastasesCastration-Resistant Prostatic Cancer+ [6]

Inactive Indication

Bone DiseasesCastration-sensitive prostate cancerHormone receptor negative HER2 positive breast cancer+ [7]

Originator Organization

Bayer AG

Active Organization

Bayer Healthcare Co., Ltd.

Bayer Pharma AG

Institute For Energy Technology

+ [6]

Inactive Organization-

License Organization

Bayer Pharma AG

China Isotope & Radiation Corp.

Drug Highest PhaseApproved

First Approval Date

United States (15 May 2013),

Castration-Resistant Prostatic Cancer

RegulationFast Track (United States), Orphan Drug (South Korea), Special Review Project (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaCl2Ra

InChIKeyRWRDJVNMSZYMDV-SIUYXFDKSA-L

CAS Registry444811-40-9

The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (
20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy.

Start Date03 Feb 2025

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+1]

NCT05924672

/ RecruitingPhase 2IIT

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis). Ra-223 is a type of therapy that emits radiation. Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells. Ra-223 is given by infusion into the veins, where it is absorbed by the bones. PSMA PET is a type of scan used to detect prostate cancer tumors. PSMA is a radioactive tracer that binds to a specific protein that is found on prostate tumor cells. The PSMA tracer shows the areas on the PET scan where tumor cells are active. A PET scan uses a special camera to detect the energy given off from radioactive tracers (such as PSMA) to make detailed pictures of areas where the tracer accumulates in the body. The PET scan is often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan, which helps to map the locations where PSMA has accumulated. PSMA PET scans may be able to select patients that will benefit the most from Ra-223 treatment.

Start Date30 Aug 2024

Sponsor / Collaborator

The University of California, San Francisco

[+1]

NL-OMON56209

/ SuspendedNot Applicable

A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY. THE DUET STUDY - DUET trial

Start Date01 Dec 2023

Sponsor / Collaborator-

100 Clinical Results associated with Radium Ra-223 Dichloride

Login to view more data

100 Translational Medicine associated with Radium Ra-223 Dichloride

Login to view more data

100 Patents (Medical) associated with Radium Ra-223 Dichloride

Login to view more data

990

Literatures (Medical) associated with Radium Ra-223 Dichloride

01 Oct 2025·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

A new era for radium-223? Optimizing treatment by balancing efficacy and toxicity through combination therapies

Review

Author: Tucci, Marcello ; Butticè, Simona ; Cozzone, Luca ; Buttigliero, Consuelo ; Angusti, Tiziana ; Parente, Antonella ; Farinea, Giovanni ; Di Stefano, Rosario Francesco ; Mogavero, Andrea

The pronounced bone tropism of prostate cancer (PCa) has prompted the development of therapies that specifically act in areas of increased bone deposition and selectively exert anti-tumor effects in osteoblastic metastases. Radium-223 dichloride is a calcium-mimetic agent that targets bone lesions, disrupting the vicious circle between tumor cells and the bone microenvironment, and it has been shown to improve survival in metastatic castration-resistant prostate cancer (mCRPC) patients. Moreover, the combination of radium-223 with androgen receptor pathway inhibitors (ARPIs), despite showing promising antitumor activity, have also produced conflicting safety results, highlighting the importance of bone health in optimizing radium-223 use. The therapeutic landscape of PCa is rapidly evolving, with several other agents approved over the past fifteen years that have repeatedly reshaped the treatment algorithm since the introduction of radium-223. Furthermore, the capacity of radium-223 to induce DNA damage in tumor cells provides a strong rationale for potential synergy with PARP inhibitors and immunotherapeutic agents. This review refocuses attention on this radionuclide, providing an updated perspective to re-evaluate the role of radium-223 in the era of radioligands and precision medicine, along with a critical overview of promising future combinations for the treatment of PCa.

03 Aug 2025·INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Radiobiological mechanisms of radium-223 dichloride: a nonclinical study

Article

Author: Baik, Jin Young ; Choi, Yiseul ; Lee, Eun Sang ; Chung, Hye Kyung

PURPOSE:

This study aimed to elucidate the radiobiological mechanisms of radium-223 dichloride ([²²³Ra]RaCl₂)-an FDA-approved agent for metastatic castration-resistant prostate cancer-by investigating its in vitro and in vivo toxic effects.

METHOD:

Using both the CCK8 and clonogenic assays, our in vitro experiments evaluated the inhibition of cell proliferation in response to variations in applied activity and exposure duration in human cancer cell lines (MDA-MB-231, BxPC3, A549, and PC3) as well as in rat pancreatic cancer cells (AR42J). Molecular analyses utilizing SDS-PAGE characterized the activation of specific cell death pathways. Additionally, an in vivo investigation employing intravenous administration further examined the systemic toxicity of [²²³Ra]RaCl₂ by monitoring animal mortality, body weight, and hematological parameters following treatment with varying activity levels (74, 148, and 222 kBq/head).

RESULTS:

[²²³Ra]RaCl₂ significantly inhibited cell proliferation in an applied activity- and time-dependent manner in human cancer cell lines, whereas AR42J cells showed relative resistance. Molecular findings revealed that BxPC3 cells underwent apoptosis via caspase-3 cleavage; PC3 cells experienced pyroptosis marked by gasdermin E (GSDME) activation and caspase-7 cleavage; and MDA-MB-231 cells exhibited enhanced PARP-1 activation indicative of DNA double-strand breaks. In vivo, treated animals demonstrated significant differences in mortality, body weight, and hematological parameters compared to controls, mirroring myelosuppressive effects typical of radiotherapy.

CONCLUSION:

The findings provide critical insights into the differential cytotoxic mechanisms of [²²³Ra]RaCl₂ across various cancer cell types and highlight its systemic toxicity in vivo. This improved understanding may facilitate the development of safer and more effective therapeutic radiopharmaceuticals based on [²²³Ra]RaCl₂.

01 Aug 2025·Clinical Genitourinary Cancer

Utilization Patterns and Survival in Older Men With Metastatic Prostate Cancer Treated with Radium-223 in the United States: A SEER-Medicare Study

Article

Author: Raval, Amit D ; Constantinovici, Niculae ; Zhou, Bo ; Sambamoorthi, Usha ; Korn, Matthew J ; McKay, Rana ; Sambamoorthi, Nethra ; Zhang, Yifan

INTRODUCTION:

Previous research on Radium-223 treatment patterns in metastatic prostate cancer has been limited to select sites, oncology practices, or claims databases. Limited data exists on the use and outcomes of Radium-223 in Medicare population the largest public insurance provider for people aged 65 years and older in the United States. Therefore, this study used a nationwide population database of cancer registries linked to Medicare claims to examine Ra-223 treatment patterns, factors associated with treatment completion, and their associations with survival outcomes.

PATIENTS AND METHODS:

A retrospective cohort analysis was conducted on 1062 Medicare beneficiaries (≥ 66 years) with prostate cancer who initiated Ra-223 treatment between January 2016 and June 2020. Eligible men had 12 months of continuous Medicare Parts A/B/D enrollment prior to Ra-223 initiation and were followed for a minimum of 6 months. Primary outcomes included completion of ≥ 5 cycles of Ra-223 and overall survival. Factors influencing completion were analyzed with multivariate logistic regression, and survival was estimated using Kaplan-Meier and proportional hazards regressions.

RESULTS:

The cohort was 79.9% nonhispanic White, 6.8% Hispanic, and 6.1% nonhispanic Black, with a mean age of 75.6 years (SD = 6.6). Overall, 59.4% completed ≥ 5 cycles. Men receiving Ra-223 as first-line (21.1%) or second-line metastatic castration-resistant prostate cancer(mCRPC) therapy (44.1%) were more likely to complete treatment than those receiving third-line or later (aOR = 1.76,1.56, 95% CI, [1.22-2.54], [1.17-2.08]). Completing ≥ 5 cycles of Ra-223 was associated with longer survival (18.5 vs. 11.1 months, P < .001; aHR = 0.51, 95% CI, [0.44, 0.59]), as was first- or second-line therapy use (18.4, 14.8 months vs. 13.8 months, P < .001; aHR = 0.56,0.82; 95% CI, [0.45-0.68], [0.69-0.96]) compared to Ra-233 as third-line or later.

CONCLUSION:

The majority of men received ≥ 5 cycles of Ra-223. Early initiation of Ra-223 was associated with higher completion rates and better survival outcomes, underscoring the importance of early Ra-223 use in managing mCRPC.

68

News (Medical) associated with Radium Ra-223 Dichloride

29 Jul 2025

·www.biopharmadive.com

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival

Artbio on Tuesday said it has added $132 million in venture funding to advance it pipeline of radiopharmaceutical drugs for cancer and grow a manufacturing network to support their production.Based in Cambridge, Massachusetts, and Oslo, Norway, and led by former Novartis executive Emanuele Ostuni, Artbio is working on several radiopharmaceuticals. The furthest along is a program called AB001, which the company is developing for metastatic castration-resistant prostate cancer. Artbiosaid it will use some of its new funding to get AB001 through mid-stage clinical trials.Radiopharmaceuticals are designed to precisely deliver radiation into tumors. After decades of research, theyve become a buzzing area of oncology research, thanks to technical advances as well as the clinical and commercial success of Novartis prostate cancer drug Pluvicto. More than a dozen startups have formed in recent years to develop radiopharmaceuticals. Multiple companies have been acquired by large drugmakers.While many of these companies are focused on similar cancer targets, theyre using different tools, such as an different radioactive isotopes or targeting molecules.For example, Pluvicto and Bayers Xofigo, an older radiopharmaceutical for prostate cancer, are built around the isotopes lutetium-177 and radium-223, respectively. AB001 instead shepherds a lead-based radioactive isotope called Pb-212 that Artbio believes can more quickly deliver radiation to tumors. Ostuni said that the drug could provoke a more durable and efficacious response in metastatic castration-resistant prostate cancer patients.Testing remains very early. Results from a small, first-in-human trial primarily evaluating safety were published in the Journal of Nuclear Medicine in May. A Phase 1 trial will begin imminently this year, said Ostuni.But Artbio is already building enough production capacity to support global studies and, eventually, commercialization. Moving quickly on manufacturing is vital because supplies of radioactive materials are limited, and the drugs have to be made and delivered via an intensive supply chain.Artbio also touts a technology that can help simplify the generation of isotopes, which Maha Katabi, a general partner at Sofinnova Investments, described in a statement as a game-changer for navigating around supply and production challenges.It's important that we don't just build a great molecule and a great clinical development program, said Ostuni, but we also build the technology to isolate the isotope and manufacture the drug product.Since its founding, Artbio has established partnerships with biotech Parabilis formerly known as FogPharma AlphaGen Therapeutics and 3B Pharmaceuticals. The company raised $90 million in Series A funding in 2023.Sofinnova Investments and B Capital led the Series B round announced Tuesday. F-Prime Capital, Omega Funds, Third Rock Ventures, Qatar Investment Authority and Alexandria Venture Investments also participated. '

Radiation TherapyAcquisition

22 Jul 2025

·www.globenewswire.com

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company’s Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology. Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy. “Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,” said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. “We’re very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.” About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com. Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@radiopharmtheranostics.com Anne Marie Fields Precision AQ (Formerly Stern IR) E: annemarie.fields@precisionaq.com Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@nwrcommunications.com.au Follow Radiopharm Theranostics: Website – https://radiopharmtheranostics.com/ Twitter – https://twitter.com/TeamRadiopharm Linked In – https://www.linkedin.com/company/radiopharm-theranostics/InvestorHub – https://investorhub.radiopharmtheranostics.com/

Executive ChangePhase 1Phase 3

09 Jul 2025

·www.biopharmadive.com

Actithera draws new investors to radiopharma drug pitch

Dive Brief:Actithera, a radiopharmaceutical drugmaker based in Oslo, Norway and Cambridge, Massachusetts, has raised just under $76 million in Series A venture financing to build out its cancer drug pipeline.In a Wednesday statement, the biotechnology company said it would use the new funds to advance into clinical development an experimental treatment targeting what are known as fibroblast activation proteins.M Ventures, which helped found the company in 2021, co-led the Series A round with Hadean Ventures, Sofinnova Partners and 4BIO Capital. Five other firms also participated.Dive Insight:Radiopharmaceuticals offer a better way to target tumor-killing radiation more precisely to cancerous cells and, accordingly, theyve drawn rising interest from drugmakers. The technology works by attaching a radioisotope to a targeting compound via a specially engineered linker molecule.While radiopharmaceuticals have been around for years Bayers Xofigo was approved in the U.S. in 2013 the field has taken off since the success of Novartis prostate cancer treatment Pluvicto. The drug earned Novartis more than $1.3 billion in 2025, giving the industry a glimpse of radiopharmaceuticals sales potential.Other large companies, like Bristol Myers Squibb and Eli Lilly, have entered the field with acquisitions of earlier-stage public biotechs.Private radiopharma companies, meanwhile, drew more than $1.1 billion since 2022 from a group of 23 venture firms tracked by BioPharma Dive.Actithera is designing its cancer drugs so they can stay in a tumor for longer by binding tightly to proteins that help a tumor grow. Founded by Andreas Goutopoulos, a veteran of Merck KGaAs U.S. subsidiary EMD Serono Inc., the biotech is focused first on an enzyme called fibroblast activation protein, or FAP.Andreas Goutopoulos, a veteran of a U.S. subsidiary of Merck KGaA, is the founder of radioligand therapy developer Actithera.Permission granted by ActitheraThe protein is expressed on cells that form connective tissue, but in cancer can support tumor growth. Actithera aims to eliminate those proteins and cancer-associated fibroblasts in a cross-fire effect that kills nearby tumor cells, Goutopoulos said.Its a way to dismantle a critical barrier to immune and therapeutic access, he wrote in an email to BioPharma Dive.Radiopharmaceuticals can be tricky to develop. Manufacturing is complex and expensive, and in response, companies like Novartis have opened dedicated production facilities. The isotope they contain also degrades over time, making the logistics of their delivery critical.Actithera is one of many up-and-coming biotechs looking to follow Novartis lead. Some of those, including Novartis and Ratio Therapeutics, are also targeting FAP.Actithera has not disclosed which cancers its targeting with its therapies. The company is preparing for clinical development in 2026 across multiple indications, Goutopoulos said.Actithera stands out as one of the most thoughtfully constructed radiopharma platforms weve seen, combining smart molecular design with a deep understanding of tumor biology and clinical need, Roger Franklin, a partner at Hadean Ventures, said in a statement. '

Drug ApprovalAcquisitionRadiation Therapy

100 Deals associated with Radium Ra-223 Dichloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Radium Ra-223 Dichloride	V10XX03	DB08913

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	China	Institute For Energy Technology	26 Aug 2020
Bone metastases	European Union	Bayer AG	13 Nov 2013
Bone metastases	Iceland	Bayer AG	13 Nov 2013
Bone metastases	Liechtenstein	Bayer AG	13 Nov 2013
Bone metastases	Norway	Bayer AG	13 Nov 2013
Castration-Resistant Prostatic Cancer	United States	Bayer HealthCare Pharmaceuticals, Inc.	15 May 2013

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-sensitive prostate cancer	Phase 3	-	Bayer AG	01 Sep 2023
Metastatic Prostate Carcinoma	Phase 3	-	Bayer AG	01 Sep 2023
Metastatic castration-resistant prostate cancer	Phase 3	United States	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	China	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	Singapore	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	Taiwan Province	Bayer AG	26 Mar 2013
Metastatic Prostatic Adenocarcinoma	Phase 2	United States	Bayer AG	28 Apr 2022
Metastatic Prostatic Adenocarcinoma	Phase 2	Brazil	Bayer AG	28 Apr 2022
Oligometastatic Prostate Carcinoma	Phase 2	United States	Bayer AG	27 Feb 2018
Relapse multiple myeloma	Phase 2	United States	Bayer AG	01 Oct 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04071236 (Phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab, ASCO2025)	Phase 1/2	Metastatic castration-resistant prostate cancer	15	Radium-223 dichloride + Peposertib 200 mg PO bid	qgzeaxfaga(hzmhhravna) = 1 patient experienced anemia cpihodhock (ljgnrevlex ) View more	Positive	30 May 2025
				Radium-223 dichloride + Peposertib 200 mg PO bid + Avelumab 800 mg IV
NCT02141438 (REASSURE, ASCO2025)	Not Applicable	Metastatic castration-resistant prostate cancer	1,472	Radium-223	bwfvnuqwbz(yuvcerdfrv) = Fractures were reported in 10% of pts and were less common in pts with (7% of 605) than without (12% of 867) concomitant BHA use jwqcjbatti (tpyvnscttn )	Positive	30 May 2025
				Docetaxel
NCT04037358 (RAVENS, Pubmed \| J Clin Oncol)	Phase 2	Oligometastatic Prostate Carcinoma ATM \| BRCA1/2 \| RB1 ... View more	64	Radium-223 (Stereotactic Ablative Radiation (SABR) MDT)	yhzaxormlo(upsamjnqkl) = uauqgndubq ztcgfqyzzj (tuxqamkvud )	Negative	07 May 2025
NCT02194842 (EORTC 1333/PEACE-3, Pubmed \| Eur Urol)	Phase 3	Fractures, Bone First line	-	Radium-223 combined with Enzalutamide	webqcghaic(trcberntel) = nwnxdpdlfr qyafvdcidj (kfblwxshlw )	Positive	01 Mar 2025
				Enzalutamide alone	webqcghaic(trcberntel) = ohbghghmhy qyafvdcidj (kfblwxshlw )
ASCO_GU2025	Not Applicable	Metastatic castration-resistant prostate cancer	61	Radium-223 re-treatment	cghuuoikxg(ieobpooxge) = kvmfepqicc gmeecaixod (srxkamiasi, 11.9 - 21.9) View more	Positive	13 Feb 2025
NCT04206319 (ASCO_GU2025)	Phase 2	Non-metastatic prostate cancer PSMA+ \| NaF+	18	Radium 223	ifeyjhtnrd(zxngzlkwsv) = Grade 2 toxicities have been rare and no Grade 1 or 2 changes in hemoglobin or platelets have occurred kvkdhvwzqv (wrdiystnzq ) View more	Positive	13 Feb 2025
NCT03002220 (EXCAAPE, CTgov)	Phase 2	Metastatic castration-resistant prostate cancer	52	radium-223	mbunsbzrty(dtyroslheu) = xmdjpmvseo phfwhtvhhf (esccsfwtnz, jvdofxteig - oiuqgifrrf) View more	-	11 Dec 2024
NCT03996473 (CTgov)	Phase 1	metastatic non-small cell lung cancer	8	Radium-223 Dichloride+Pembrolizumab (Radium-223 Dichloride + Pembrolizumab)	zngcoegqae = ewpjtwfeud fqnqpkdovc (vrpwhyrwth, tmwudtkjdh - xllecpeusx) View more	-	10 Oct 2024
				Radium-223+Pembrolizumab (Radium-223 + Pembrolizumab)	splqhlnwew(lbzwdvwjyq) = sztbnsxroh fwpvofsypr (fryvczbxqa, diowyntwms - qnwaegdzpm) View more
ASTRO2024	Not Applicable	Oligometastatic Prostate Carcinoma	-	RAdium-223 (Stereotactic ablative radiation (SABR))	gxmynrdjno(nhiildjxgb) = 13 patients (20%) experienced grade 3 toxicity (no grade 4 or 5), of which 6 were non-treatment-related, 2 related to SABR, and 5 related to SABR/Ra223 (lymphopenia, back pain) wnvibhdaoy (csqondrhsy )	-	01 Oct 2024
NCT02141438 (REASSURE, EANM2024)	Not Applicable	Metastatic castration-resistant prostate cancer ALP levels	811	Radium-223 (Normal ALP/Decline)	qnscanyyla(nzvfryiqkn) = fjipyrsdzw vygbeagblu (rfkmcjqzec ) View more	Positive	27 Sep 2024
				Radium-223 (Normal ALP/No Decline)	qnscanyyla(nzvfryiqkn) = cykkxmtbwg vygbeagblu (rfkmcjqzec ) View more